| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.3 | 0.08 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.08 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.08 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.099 | 0.08 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.051 | 0.08 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.093 | 0.08 |